Acceptability of Fluzone Intradermal Vaccine to Patients and Vaccine Administrators
|ClinicalTrials.gov Identifier: NCT01716130|
Recruitment Status : Completed
First Posted : October 29, 2012
Last Update Posted : October 29, 2012
|Condition or disease|
|Patient Response to Fluzone ID Vaccine|
|Study Type :||Observational|
|Actual Enrollment :||249 participants|
|Official Title:||Acceptability of Fluzone Intradermal Vaccine to Patients and Vaccine Administrators|
|Study Start Date :||October 2011|
|Primary Completion Date :||November 2011|
|Study Completion Date :||November 2011|
IM vaccine in the past 3 years
Those subjects that received the Fluzone ID influenza vaccine, and reported having received the IM influenza vaccine in the past three years.
no IM vaccine in the past 3 years
Patients that received the Fluzone ID vaccine and reported not receiving the IM influenza vaccine in the past 3 years.
Those experienced vaccine administrators that administered the Fluzone ID vaccine, and were then surveyed concerning safety and overall satisfaction with the ID vaccine in comparison to the IM vaccine.
- Overall patient satisfaction with intradermal vaccine [ Time Frame: 7 days ]Overall patient satisfaction was assessed immediately post-vaccination and seven days later by patient survey.
- Overall satisfaction with the Fluzone ID vaccine by vaccine administrators [ Time Frame: seven days ]Vaccine administrators (#8)completed a survey rating the ID vaccine in comparison to the IM vaccine in terms of ease of vaccine preparation, time required to administer the vaccine, and safety/needle stick risk for patients and administrators.
- Overall satisfaction with the Fluzone ID vaccine in two cohort groups [ Time Frame: 7 days ]Using a survey tool, patients receiving the Fluzone ID vaccine were separated into 2 groups: 1) those that reported receiving the IM influenza vaccine in the past 3 years; and 2) those that reported not receiving the IM influenza vaccine in the past 3 years. All subject's satisfaction was assessed by survey immediately post-vaccination and 7 days later. Survey responses were compared between the 2 groups. The group that reported receiving the IM influenza vaccine in the past 3 years was asked to compare their experience with the ID vaccine in comparison to the IM vaccine.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01716130
|United States, California|
|Touro University California|
|Vallejo, California, United States, 94592|
|Principal Investigator:||James E Foy, D.O.||Touro University, California|